格尔提尼布在Ib期试验中显示,在患有HER2突变的晚期NSCLC患者中,该药物具有前期可靠性,达到66. 7%的ORR和高的DCR,同时耐受性良好. Zongertinib in Phase Ib trial shows promise for advanced NSCLC patients with HER2 mutations, achieving 66.7% ORR and high DCR, while being well-tolerated.

Boehringer Ingelheim的zongertinib在对HER2突变的高级非小细胞肺癌患者进行一B试验的阶段一B试验中,取得了令人乐观的结果,达到了66.7%的客观反应率和高的疾病控制率。 Boehringer Ingelheim's zongertinib has shown promising results in a Phase Ib trial for advanced non-small cell lung cancer (NSCLC) patients with HER2 mutations, achieving a 66.7% objective response rate and high disease control rates. 这种治疗得到很好的容忍,由于副作用,停止治疗的比例较低。 The treatment was well tolerated, with low discontinuation due to side effects. zongertinib和Bayer的BAY 2927088正在第三阶段试验中,为现有疗法有限的病人提供了新的可能选择。 Both zongertinib and Bayer's BAY 2927088 are in ongoing Phase III trials, offering potential new options for patients with limited existing therapies.